Medicine and Dentistry
Patient
100%
Erlotinib
77%
Non Small Cell Lung Cancer
66%
Epidermal Growth Factor Receptor
66%
Elderly Patient
44%
Monotherapy
33%
Diseases
22%
Combination Therapy
22%
Disease Exacerbation
22%
Overall Survival
22%
Progression Free Survival
22%
Phase II Trials
22%
Recurrent Disease
11%
Adverse Event
11%
Toxicity
11%
Steroid Therapy
11%
Malignant Neoplasm
11%
Adenocarcinoma
11%
Exanthem
11%
Acneiform Eruption
11%
Age
11%
Drug
11%
Chemotherapeutic Agent
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Interstitial Lung Disease
11%
Therapeutic Procedure
11%
Female
11%
Oncology
11%
Pharmacology, Toxicology and Pharmaceutical Science
Erlotinib
77%
Epidermal Growth Factor Receptor
66%
Non Small Cell Lung Cancer
66%
Monotherapy
33%
Diseases
22%
Disease Exacerbation
22%
Overall Survival
22%
Progression Free Survival
22%
Cytotoxic Chemotherapy
22%
Toxicity
11%
Adverse Event
11%
Recurrent Disease
11%
Epidermal Growth Factor Receptor Kinase Inhibitor
11%
Adenocarcinoma
11%
Malignant Neoplasm
11%
Drug
11%
Rash
11%
Interstitial Lung Disease
11%
Acne
11%